Home > Resources > Whitepapers > The Year in CRISPRs

The Year in CRISPRs

December 17, 2017

The news was full of CRISPR developments in 2015. New insights into the structures and mechanisms of CRISPR systems were reported. New tools and techniques were introduced. And new applications were explored. The newest CRISPR developments usually appear in peer-reviewed studies that emphasize incremental improvements. These studies tend to be highly focused and technically oriented, and hence fairly narrow. Taken as a whole, however, CRISPR studies form a broad and steadily advancing front, as this ebook demonstrates.

Spotlight

Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company with big ambitions. We aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (Bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology.

OTHER WHITEPAPERS

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More

Lentivirus production study in the scale-X™ fixed-bed bioreactor

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Read More

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More

Imaweld® heat sealable & weldable tube bioprocess media

whitePaper | February 3, 2023

Imaweld® is thermoplastic elastomer tubing particularly designed to transfer critical fluid in pharmaceutical and biopharmaceutical applications.

Read More

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More

Lentivirus production study in the scale-X™ fixed-bed bioreactor

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Read More

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or
72 physiological conditions has become of wide interest due to their potential to address serious
73 unmet medical needs.

Read More

Imaweld® heat sealable & weldable tube bioprocess media

whitePaper | February 3, 2023

Imaweld® is thermoplastic elastomer tubing particularly designed to transfer critical fluid in pharmaceutical and biopharmaceutical applications.

Read More

More Whitepapers

Spotlight

Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company with big ambitions. We aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (Bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference